TIDMANA
RNS Number : 9287R
Ananda Developments PLC
01 November 2023
1 November 2023
ANANDA DEVELOPMENTS PLC
("Ananda", the "Company" or the "Group")
MOU signed with Nottingham Trent University
Ananda Developments plc (AQSE: ANA) and its wholly owned
subsidiary DJT Plants Limited ("DJT") have signed a Memorandum of
Understanding ("MOU") with Nottingham Trent University ("NTU") to
pursue third-party grant funding to progress DJT's medical cannabis
breeding programme and its low carbon medical cannabis cultivation
and manufacturing. The shared vision, beyond the MOU, is to create
a formal Strategic Partnership and the establishment of a
Cannabinoid Centre of Excellence at NTU.
Highlights
-- Ananda, DJT and NTU will combine their expertise and
resources to pursue third-party grant funding to progress DJT's
breeding and genetics programme as well as its low carbon cannabis
cultivation and manufacturing.
-- NTU's expertise includes Dr Gareth Cave who has previously
conducted research into medical cannabis and has held a Schedule
One Home Office licence to cultivate and research cannabis produced
products, and Dr Chungui Lu, Professor in Sustainable Agriculture
specialising in plant genomics and plant molecular biology.
-- The initial focus will be to build on the success of the
genetics and breeding programme and on packaging DJT's low carbon
cultivation into a wider pharmaceutical innovation project to
attract major grant funding.
-- The shared vision, beyond the MOU, is to create a formal
Strategic Partnership and the establishment of a Cannabinoid Centre
of Excellence at NTU.
Ananda's CEO, Melissa Sturgess commented: "By partnering with
NTU we can progress our breeding and genetics programme with the
aid of non-dilutionary funding and with the additional resources
and expertise of NTU. We can also develop the medical cannabis
cultivation and manufacturing proposition around its sustainability
credentials to seek significant grant funding for this
business.
"The two years of genetics research and scaled cultivation
trials we have undertaken at our Lincolnshire site have put us in a
position to form this partnership, allowing us to take our hard-won
proprietary knowledge through to commercialisation at a lower cost
than previously envisaged.
"With patient numbers in the United Kingdom now around 30,000
and increasing month on month, this partnership will allow us to
continue to build our skills and intellectual property to ensure we
are ready to take advantage of commercial opportunities when market
trends permit, without incurring the significant monthly costs
being incurred under the previous strategy. We look forward to
updating shareholders as we secure grant funding with our new
partners."
Prof Richard Emes, Pro-Vice Chancellor of Research &
Innovation said: "We are delighted to be partnering our research
expertise with Ananda and DJT. Our research scientists look forward
to being part of this very important journey to develop products
that will positively change the lives of so many people."
Further information on the MOU
The MOU between Ananda, DJT and NTU will commence from 1
November 2023.
Ananda and DJT will bring to the partnership their collective
proprietary background IP, expertise, methods, protocols, cannabis
seed inventory and data to allow the recommencement of the genetics
stabilisation programme. The Group will also provide the use of the
existing research facility in Lincolnshire, if and when
required.
NTU will provide its research capability and expertise, and work
with Ananda and DJT through its grant capture team to pursue grant
funding for the Partnership, including the drafting and submission
of grant applications.
Ananda, DJT and NTU will form the first stage of the Strategic
Partnership by seeking third-party funding for collaborative
Knowledge Transfer Partnership projects, with a vision to establish
a Cannabinoid Centre of Excellence at NTU based on the respective
know-how of the parties.
The Cannabinoid Centre of Excellence will aim to add
significantly to the scientific body of knowledge in the UK
regarding medicinal cannabis, its cultivation, breeding and
genetics, and its use to treat various human health conditions. It
will aim to become a world leading Centre in this area by activity
and reputation.
As part of the aim to establish a Cannabinoid Centre of
Excellence, Ananda, DJT and NTU have also agreed to collaborate on
the development of a broader pipeline of research and to seek grant
funding for these additional research projects.
The MOU does not transfer ownership over any of the IP or
proprietary information that Ananda and DJT and NTU separately,
have developed to date. Ownership of any IP developed through the
Strategic Partnership will be determined by negotiation between the
parties as the MOU progresses to formal agreements.
Nottingham Trent University
NTU is an educational institute undertaking research &
innovation from fundamental discovery to delivery of, technology
and knowledge transfer. With over 40,000 students across five
university sites, it is one of the largest and most influential
higher education institutions in the country. NTU's expertise
ranges from disciplines in Plant Genomics, Plant Breeding, Plant
Active Ingredients Chemistry and Sustainability for ESG and SDG
compliance, through to wider Talent Attraction & Retention and
Executive Development support. Further information on NTU is
available at https://www.ntu.ac.uk .
To stay abreast of the latest developments at Ananda, we
encourage you to follow our social media channels which are:
-- Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
-- LinkedIn : https://www.linkedin.com/company/anadevelopments/
-- Twitter : https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
ir@anandadevelopments.com
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP +44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a
leading provider of cannabinoid-based medicines for the treatment
of complex, chronic inflammatory pain conditions.
For more information, please visit:
https://anandadevelopments.com/
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public do
main.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXFDFFWFEDSEES
(END) Dow Jones Newswires
November 01, 2023 03:00 ET (07:00 GMT)
Ananda Developments (AQSE:ANA)
過去 株価チャート
から 11 2024 まで 12 2024
Ananda Developments (AQSE:ANA)
過去 株価チャート
から 12 2023 まで 12 2024
